title: Role of paraoxonase 1 (PON1) in organophosphate metabolism: implications in neurodegenerative diseases.
abstract: Organophosphate pesticides are a class of compounds that are widely used in agricultural and rural areas. Paraoxonase 1 (PON1) is a phase-I enzyme that is involved in the hydrolysis of organophosphate esters. Environmental poisoning by organophosphate compounds has been the main driving force of previous research on PON1 enzymes. Recent discoveries in animal models have revealed the important role of the enzyme in lipid metabolism. However although PON1 function is well established in experimental models, the contribution of PON1 in neurodegenerative diseases remains unclear. In this minireview we summarize the involvement of PON1 genotypes in the occurrence of Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis. A brief overview of latest epidemiological studies, regarding the two most important PON1 coding region polymorphisms PON1-L55M and PON1-Q192R is presented. Positive and negative associations of PON1 with disease occurrence are reported. Notably the MM and RR alleles contribute a risk enhancing effect for the development of some neurodegenerative diseases, which may be explained by the reduced lipoprotein free radical scavenging activity that may give rise to neuronal damage, through distinct mechanism. Conflicting findings that fail to support this postulate may represent the human population ethnic heterogeneity, different sample size and environmental parameters affecting PON1 status. We conclude that further epidemiological studies are required in order to address the exact contribution of PON1 genome in combination with organophosphate exposure in populations with neurodegenerative diseases.
authors.affiliation: Center of Toxicology Science and Research, University of Crete, Heraklion, Crete, Greece.
authors.forename: Vasilis P
authors.initials: VP
authors.lastname: Androutsopoulos
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Kanavouras
authors.forename: Aristidis M
authors.initials: AM
authors.lastname: Tsatsakis
mesh_terms: D000544:Alzheimer Disease / Q000139:chemically induced / Q000201:enzymology / Q000235:genetics; D000690:Amyotrophic Lateral Sclerosis / Q000139:chemically induced / Q000201:enzymology / Q000235:genetics; D000818:Animals; D043303:Aryldialkylphosphatase / Q000235:genetics / Q000502:physiology*; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D019636:Neurodegenerative Diseases / Q000139:chemically induced / Q000201:enzymology*; D009943:Organophosphorus Compounds / Q000633:toxicity*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000201:enzymology / Q000235:genetics
chemical_list: D009943:Organophosphorus Compounds; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human